Abstract Background and Aim Previous smaller meta‐analyses comparing the incidence of
hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir …

Simple Summary Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are the preferred
anti-viral agents used as first-line treatments for chronic hepatitis B. Despite many meta …

Background Chronic viral hepatitis B, C, and D are the main causes of decompensated
cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more …

Simple Summary We developed a novel risk-scoring model for hepatocellular carcinoma
development in treatment-naïve patients with chronic hepatitis B virus infection who are …

Chronic hepatitis B virus (HBV) infection is a worldwide health problem leading to severe
liver dysfunction, including liver cirrhosis and hepatocellular carcinoma. Although current …

Simple Summary It is still controversial whether tenofovir disoproxil fumarate (TDF) has a
lower risk of hepatocellular carcinoma (HCC) development than entecavir (ETV) in patients …

Background At present, there are a variety of antiviral drugs for HBV in clinical practice, but
there is no standard scheme for transcatheter arterial chemoembolization (TACE) combined …

Abstract Zur Therapie der chronischen Hepatitis-B-Virus-(HBV-) Infektion stehen aktuell
pegyliertes Interferon-Alpha und Nucleosid-/Nucleotidanaloga (Entecavir und Tenofovir) zur …

Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are equally recommended as first-
line treatments for antiviral treatment-naïve (ART-naïve) chronic hepatitis B (CHB) patients …

Background: Tenofovir and Entecavir are recommended as the first-line medicine of
treatment for chronic hepatitis B. The occurrence of hepatocellular carcinoma after the …